OSX

0.00%

3.9¢ osteopore limited

I'll save you the research, it's next to none. At this...

First 9 Last

Share
Profile

Follow
Eqz

3,424 Posts.

1116

21/06/21

19:28

Post #: 53974181
Share

Originally posted by candidcamera: ↑

I'd have to look into microcap biotechs to give a proper answer on which ones have revenues that justify their MC. I would think few, if any, as they need plenty of money just to keep the doors open, for research and development, weathering the setbacks of regulatory storms and poor test results and making wrong corporate turns, before they see success.

But this is precisely the reason I chose to go into OSX. Sure, they're a microcap, but different from many other biotech microcaps, in that they had already been around for twenty years, done the research, developed the products, got the permissions, had great results from operations, etc. I wrongly assumed they could capitalise on all of this to produce a fast increase of revenue, aided by new products, great additions to the board, strong partnerships, etc.

A quick glance at the share price history of successful biotechs reveals that many years of patience is required. There are many large ones (e.g Resmed) that started as microcaps, probably had low revenue for a long time and took years to take off (but never traded lower than their listing price). I would think OSX products will find success one day. My issue is the the time it will take. That's not a complaint against the board, products or sales teams. As I mentioned, the issue is that doctors are not using the products, therefore hospitals are not buying them in sufficient quantities to seriously up the revenue and move the share price.

I had hopes of a fast increase in revenue and based my decision to buy on that. It was wrong. To paraphrase Shakespeare, the problem lies not with the company but with my expectations. I think OSX faces many years – as most biotechs have – before the kind of results I was thinking of, and that's just too long for me. For someone else who's happy to keep it in the bottom drawer and wait, I'm sure they'll see a good return.

Expand

I'll save you the research, it's next to none. At this phase of a biotech, the valuation is based on its TAM and current phase of its pipeline.

We will just have to wait and see how the management team will execute their the growth journey, so far the US market is a dead set a flop. They will need to focus on the Asia markets where they have some penetration already.

Else get acquired by a larger player.

OSX Price at posting: 45.0¢ Sentiment: None Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

VUL

Vulcan appoints investment bank and M&A veteran to board

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

There are more pages in this discussion • 2 more messages in this thread...

First 9 Last

Add OSX (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.000(0.00%)		Mkt cap ! $4.506M

Open	High	Low	Value	Volume
4.0¢	4.0¢	3.9¢	$14.66K	375.4K

Buyers (Bids)

No.	Vol.	Price($)
3	408890	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	139119	2

View Market Depth

No.	Vol.	Price($)
2	378890	0.039
2	1000000	0.038
2	219080	0.037
1	83330	0.036
2	205710	0.035

Price($)	Vol.	No.
0.040	139119	2
0.041	621	1
0.042	106352	2
0.043	34483	1
0.044	409090	1

Last trade - 16.10pm 13/09/2024 (20 minute delay)

OSX (ASX) Chart

I'll save you the research, it's next to none. At this...

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Utah authorities sign off on Anson's lithium extraction plans at Green River

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Vulcan appoints investment bank and M&A veteran to board

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I&apos;ll save you the research, it&apos;s next to none. At this...

Top Stories

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Utah authorities sign off on Anson's lithium extraction plans at Green River

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Vulcan appoints investment bank and M&A veteran to board

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'll save you the research, it's next to none. At this...